#	Pagina
attuale pagina	/open-h2020/projects/224894/index.html

Opendata, web and dolomites

ONCORNET2.0 SIGNED

ONCOgenic Receptor Network of Excellence and Training 2.0

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

ONCORNET2.0 project word cloud

Explore the words cloud of the ONCORNET2.0 project. It provides you a very rough idea of what is the project "ONCORNET2.0" about.

skill nanobodies discovery scientists oncornet2 transferable delivered generation microscopy multiple brings ackr3 gender multidisciplinary chemokine responsible integral technological exposure integrates team surface crispr biological network balanced intersectoral commercialisation cancer progression stage receptors 20 em excellence successfully cell etn fundamental gpcr functions burden incorporate yield cxcr4 cellular regulating rarely drug druggable oncornet moving proteins blended incorporation talented first deaths gpcrs 15 mechanisms protein understand ground successful modulation scientific strategies health cas biology industries critical coupled leads skills pis expressed fast photochemistry builds poorly interdisciplinary cryo breaking young learning esrs oncogenic play tumours academically training extensive demand groups leveraging therapeutic

Project "ONCORNET2.0" data sheet

The following table provides information about the project.

Coordinator	STICHTING VU Organization address address: DE BOELELAAN 1105 city: AMSTERDAM postcode: 1081 HV website: www.vu.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Total cost	4˙099˙781 €
EC max contribution	4˙099˙781 € (100%)
Programme	1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
Code Call	H2020-MSCA-ITN-2019
Funding Scheme	MSCA-ITN-ETN
Starting year	2020
Duration (year-month-day)	from 2020-02-01 to 2024-01-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	STICHTING VU STICHTING VU Organization address address: DE BOELELAAN 1105 city: AMSTERDAM postcode: 1081 HV website: www.vu.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (AMSTERDAM)	coordinator	1˙062˙479.00
2	THE UNIVERSITY OF NOTTINGHAM THE UNIVERSITY OF NOTTINGHAM Organization address address: University Park city: NOTTINGHAM postcode: NG7 2RD website: www.nottingham.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (NOTTINGHAM)	participant	606˙345.00
3	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS Organization address address: RUE MICHEL ANGE 3 city: PARIS postcode: 75794 website: www.cnrs.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	549˙604.00
4	UNIVERSITY OF GLASGOW UNIVERSITY OF GLASGOW Organization address address: UNIVERSITY AVENUE city: GLASGOW postcode: G12 8QQ website: www.gla.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (GLASGOW)	participant	303˙172.00
5	INTERAX BIOTECH AG INTERAX BIOTECH AG Organization address address: PARK INNOVAARE city: VILLINGEN postcode: 5234 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (VILLINGEN)	participant	281˙276.00
6	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE Organization address address: RUE DE TOLBIAC 101 city: PARIS postcode: 75654 website: www.inserm.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	274˙802.00
7	QVQ HOLDING BV QVQ HOLDING BV Organization address address: YALELAAN 1 KAMER 0270 city: UTRECHT postcode: 3584 CL website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (UTRECHT)	participant	265˙619.00
8	MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC) MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC) Organization address address: ROBERT ROSSLE STRASSE 10 city: BERLIN postcode: 13125 website: www.mdc-berlin.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BERLIN)	participant	252˙788.00
9	Universitätsklinikum Jena Universitätsklinikum Jena Organization address address: Bachstraße 18 city: Jena postcode: 7743 website: www.uniklinikum-jena.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (Jena)	participant	252˙788.00
10	UNIVERSIDAD AUTONOMA DE MADRID UNIVERSIDAD AUTONOMA DE MADRID Organization address address: CALLE EINSTEIN 3 CIUDAD UNIV CANTOBLANCO RECTORADO city: MADRID postcode: 28049 website: http://www.uam.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (MADRID)	participant	250˙904.00

Map

Project objective

Cancer is a major health burden responsible for 20% of European deaths. There is a critical need to understand its fundamental biological mechanisms. G protein-coupled receptors (GPCRs) are cell surface proteins which play an important role in regulating cellular functions integral to cancer biology and, as highly druggable proteins, oncogenic GPCRs are important therapeutic targets. ONCORNET2.0 builds on the success of ONCORNET (Oncogenic GPCR Network of Excellence and Training), a first-in-kind ETN in GPCR drug discovery that has successfully delivered scientific advance and training to talented early stage researchers (ESRs). ONCORNET2.0 will incorporate recent scientific and technological advances to understand and target two oncogenic GPCRs; the chemokine receptors CXCR4 and ACKR3. These are highly expressed in multiple tumours but their role in cancer progression remains poorly understood. We will develop new strategies for CXCR4/ACKR3 modulation (photochemistry, nanobodies) and investigate their effects on oncogenic responses, to yield key new knowledge and potential leads for drug development and commercialisation. ONCORNET2.0 will bring together the leading GPCR research groups in Europe and 15 ESRs. By leveraging on the success and experience of ONCORNET and recent ground-breaking advances in the field of GPCRs (e.g. cryo-EM, CRISPR-Cas, advanced microscopy), ONCORNET2.0 brings a young, gender-balanced team of PIs to target oncogenic GPCRs. The consortium will offer an extensive multidisciplinary training programme for ESRs ensuring their successful incorporation in today’s fast-moving drug development programmes. This programme integrates both research and transferable skill sets through blended learning. Our aim is that, through training these ESRs with interdisciplinary and intersectoral exposure, we will develop the next generation of scientists with skills that are in high demand by the drug development industries but rarely offered academically.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCORNET2.0" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCORNET2.0" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

NL4XAI (2019)

Interactive Natural Language Technology for Explainable Artificial Intelligence

Read More

ORBITAL (2019)

Ocular Research By Integrated Training And Learning

Read More

INSPIRE (2019)

INNOVATIVE GROUND INTERFACE CONCEPTS FOR STRUCTURE PROTECTION

Read More